Elsevier established a free COVID-19 resource centre in January 2020, offering information in English and Mandarin. The centre provides access to research for PubMed Central and other repositories. The International Society on Thrombosis and Haemostasis (ISTH) issued interim guidance on managing coagulopathy in COVID-19. Coagulopathy is a significant poor prognostic feature in severe cases, often linked to sepsis. The guidance recommends using laboratory parameters like D-dimers, prothrombin time (PT), and platelet count for risk stratification. D-dimers are particularly important, with elevated levels indicating higher mortality risk. Patients with markedly increased D-dimers may require hospital admission even without other severe symptoms. PT and platelet count also show subtle changes, but INR may obscure these. Thrombocytopenia is not consistently predictive of mortality in COVID-19. Monitoring coagulation markers like fibrinogen is recommended. Prophylactic low molecular weight heparin (LMWH) is advised for hospitalized patients, especially those with high D-dimer levels. LMWH reduces mortality and protects against venous thromboembolism. Bleeding is rare, but management follows septic coagulopathy guidelines. Experimental therapies like anti-thrombin and hydroxychloroquine are considered. The guidance is interim and may be updated as knowledge evolves.Elsevier established a free COVID-19 resource centre in January 2020, offering information in English and Mandarin. The centre provides access to research for PubMed Central and other repositories. The International Society on Thrombosis and Haemostasis (ISTH) issued interim guidance on managing coagulopathy in COVID-19. Coagulopathy is a significant poor prognostic feature in severe cases, often linked to sepsis. The guidance recommends using laboratory parameters like D-dimers, prothrombin time (PT), and platelet count for risk stratification. D-dimers are particularly important, with elevated levels indicating higher mortality risk. Patients with markedly increased D-dimers may require hospital admission even without other severe symptoms. PT and platelet count also show subtle changes, but INR may obscure these. Thrombocytopenia is not consistently predictive of mortality in COVID-19. Monitoring coagulation markers like fibrinogen is recommended. Prophylactic low molecular weight heparin (LMWH) is advised for hospitalized patients, especially those with high D-dimer levels. LMWH reduces mortality and protects against venous thromboembolism. Bleeding is rare, but management follows septic coagulopathy guidelines. Experimental therapies like anti-thrombin and hydroxychloroquine are considered. The guidance is interim and may be updated as knowledge evolves.